REVIEWWhat cardiologists should know about cardiac sarcoidosis in 2022?Lemay, Sylvain; Marchand, Laurie; Sénéchal, Mario Author Information Department of Cardiology, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Quebec City, Quebec, Canada Correspondence to Mario Sénéchal, MD, Associate Professor, Faculty of Medicine, Laval University, Institut universitaire de cardiologie et de pneumologie de Québec, 2725 Chemin Sainte-Foy, Quebec, QC G1V 4G5, Canada. Tel: +418 656 8711; fax: +418 656 8157; e-mail: [email protected]laval.ca Current Opinion in Cardiology: July 12, 2022 - Volume - Issue - 10.1097/HCO.0000000000000970 doi: 10.1097/HCO.0000000000000970 Buy PAP Metrics Abstract Purpose of review Cardiac sarcoidosis (CS) is a potentially fatal condition when unrecognized or not treated adequately. The purpose of this review is to provide new strategies to increase clinical recognition of CS and to present an updated overview of the immunosuppressive treatments using most recent data published in the last 18 months. Recent findings CS is an increasingly recognized pathology, and its diagnostic is made 20 times more often in the last two decades. Recent studies have shown that imaging alone usually lacks specificity to distinguish CS from other inflammatory cardiomyopathies. However, imaging can be used to increase significantly diagnostic yield of extracardiac and cardiac biopsy. Recent reviews have also demonstrated that nearly 25% of patients will be refractory to standard treatment with prednisone and that combined treatment with a corticosteroid-sparing agent is often necessary for a period that remains undetermined. Summary CS is a complex pathology that should always require a biopsy attempt to have a histological proven diagnosis before starting immunosuppressive therapy consisting of corticosteroids with or without a corticosteroid-sparing agent. Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.